Q-omics provides the consensus-scored MS4A6E profile across patient tissues and cancer cell-line models. MS4A6E expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MS4A6E is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, MS4A6E RNA expression shows 8,580 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where MS4A6E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A6E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A6E survival associations across molecular data types. MS4A6E RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A6E RNA expression–survival associations across cancer types. High MS4A6E expression shows unfavorable associations in ACC, PCPG and STAD, but favorable associations in PAAD, BRCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MS4A6E RNA expression.
This table summarizes MS4A6E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A6E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A6E shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, THCA, STAD and BLCA. The KIRC box plot shows higher MS4A6E RNA expression in tumor versus normal tissue (log2 FC = +0.185, t-test p < 0.001).
This table shows molecular features associated with MS4A6E in patient tissues and cancer cell lines. In patient samples, MS4A6E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A6E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
